Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Total Non-Current Liabilities (2016 - 2025)

Guided Therapeutics' Total Non-Current Liabilities history spans 13 years, with the latest figure at $694000.0 for Q4 2025.

  • On a quarterly basis, Total Non-Current Liabilities rose 519.64% to $694000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $694000.0, a 519.64% increase, with the full-year FY2025 number at $694000.0, up 519.64% from a year prior.
  • Total Non-Current Liabilities hit $694000.0 in Q4 2025 for Guided Therapeutics, up from $79000.0 in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for GTHP hit a ceiling of $1.8 million in Q4 2021 and a floor of $35000.0 in Q2 2025.
  • Historically, Total Non-Current Liabilities has averaged $870950.0 across 5 years, with a median of $710500.0 in 2023.
  • Biggest five-year swings in Total Non-Current Liabilities: tumbled 90.6% in 2024 and later surged 519.64% in 2025.
  • Tracing GTHP's Total Non-Current Liabilities over 5 years: stood at $1.8 million in 2021, then decreased by 22.95% to $1.4 million in 2022, then crashed by 51.74% to $666000.0 in 2023, then tumbled by 83.18% to $112000.0 in 2024, then surged by 519.64% to $694000.0 in 2025.
  • Business Quant data shows Total Non-Current Liabilities for GTHP at $694000.0 in Q4 2025, $79000.0 in Q3 2025, and $35000.0 in Q2 2025.